Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Technology

NGeneBio Co., Ltd. Goes Public… Mixed Reactions to Fundraising at PROTEINA CO., LTD. and ADBIOTECH Co.,Ltd. [Bio Spotlight]

On the 5th, in the biotech and healthcare sector, NGeneBio Co., Ltd.(354200)hit the daily price limit following news of a patent for precision leukemia diagnostic technology, while #PROTEINA CO., LTD.…
  • 2026-11-07 07:52:02
  • KIM SAE-MI
Technology

A Miracle Cancer Drug That Was Powerless Against Solid Tumors… A Hail-Mary Play on the “Double Helix”

Philadelphia, USA, 2012. At the time, Tom and CARRY Whitehead visited the Children’s Hospital of Philadelphia (CHOP) with their six-year-old daughter, Emily, who was suffering from acute lymphoblastic…
  • 2026-11-07 07:31:03
  • KIM SUNG-JIN
Technology

A Question Posed to a Doctor Searching for a Cancer Cure… “When Will You Go Public?”

“If you can go public within two years, I’ll invest 20 billion won.”Professor Song Si-young, an emeritus professor at Yonsei University College of Medicine and the head of the biotech firm Cowell Biod…
  • 2026-11-07 07:01:03
  • KIM SUNG-JIN
Technology

O Il-hwan, CEO of RegeneInnoPharm: “Korea’s First miRNA New Drug Clinical Trial… Taking on the Challenge of Diabetic Foot Regeneration”

Oh Il-hwan, CEO of Regene InnoPharm, sat down for an interview with Edaily at the company’s office in Seocho-gu, Seoul, on the 30th of last month. (Photo: ReporterKIM SAE-MI ) “While existing trea…
  • 2026-11-07 07:01:02
  • KIM SAE-MI
Lifestyle

CELL BIOTECH CO ., LTD Expected to Surpass 20 Billion Won in Health Supplement Sales in Europe… Accelerating ‘Export Drive’

CELL BIOTECH CO ., LTD(049960), a company specializing in the microbiome, is achieving remarkable results in the European market—the leading region for probiotics. Having overcome stringent entry barr…
  • 2026-11-07 06:42:02
  • YU JIN-HEE
Technology

Next Year Will Be Decisive for Aptabio Therapeutics Inc.’s New Kidney Drug… CEO Lee Soo-jin: “65% Enrollment in Phase 2b Trial”

Aptabio Therapeutics Inc.(293780)has completed approximately 65% of patient enrollment for the domestic Phase 2b clinical trial of “Isuzinacxib” (APX-115), a treatment for diabetic nephropathy. As it …
  • 2026-11-06 11:02:02
  • NA EUN-KYUNG
Technology

HLB INC. Shares Plunge as AriBio Surges [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks showed sharply divergent performance on Nov. 4 despite gains in the broader market. HLB INC. and its affiliates tumbled after a U.S. regulatory dec…
  • 2026-11-06 08:12:02
  • NA EUN-KYUNG
Technology

HLB INC. Plummets as Hopes for ‘Approval by Year-End’ Fade… Hugel, Inc.’s Earnings Shock, AriBio Hits Daily Limit Up [Bio Market Roundup]

On the 4th, both the KOSPI and KOSDAQ rose, and the pharmaceutical and biotech sectors also performed strongly. The KOSPI Pharmaceutical Index and the KOSDAQ Pharmaceutical Sector Index rose 3.44% and…
  • 2026-11-06 08:11:01
  • NA EUN-KYUNG
Technology

Same Ring, Different Battlegrounds… Why SkyLabs Is Bound to Surpass Oura

While the global leader in smart rings has seen its initial public offering (IPO) delayed, South Korea’s leading smart ring company is gaining ground in terms of market capitalization.While Finnish sm…
  • 2026-11-06 08:01:06
  • Kim Seung-kwon
Technology

Graphy Bets on 3D-Printed Teeth as Its Next Growth Driver, Plans Production Lab in Brazil

South Korean dental materials manufacturer Graphy Inc. is expanding into 3D-printed dental restorations, including crowns and bridges, as it seeks to establish a new growth engine beyond its flagship …
  • 2026-11-06 08:01:05
  • NA EUN-KYUNG
1 2 3 4 5 6 7 8 9 10 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English